Approved indication · Premenopausal HSDD
PT-141 for Women: The Approved HSDD Indication
The one use the FDA approval covers — and what the RECONNECT trials, the 52-week extension, and the mechanism imaging actually found.
The short version
Here is PT-141 for women in plain terms. This is the single use the FDA approved: low sexual desire that causes real distress in premenopausal women — HSDD (hypoactive sexual desire disorder) [3][6]. In two big trials, the drug beat a placebo on desire and on the distress that low desire causes — a real but small win [3]. Brain-imaging work shows it acts on desire circuits, with the effect lasting up to about a day [5]. It is given as a single injection under the skin, as needed. The cited detail follows.
What does PT-141 do for women?
For women, PT-141 (bremelanotide) is the approved treatment for premenopausal HSDD — acquired, generalized low desire that causes marked distress [3][6]. Mechanistically, it acts on the brain rather than on the body's circulation: in a crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and altered how the brain processed erotic stimuli, consistent with a central mechanism rather than a blood-flow one [5]. The animal groundwork pointed the same way — in female rats, the compound selectively increased desire-driven solicitation behavior [2]. A preclinical review consolidated this central, brain-level account of how melanocortin activation modulates appetitive female sexual behavior [8].
How well does it work, honestly
The benefit is real but modest, and it is fair to say so plainly. In the two RECONNECT Phase 3 trials (n=1267 premenopausal women with HSDD), bremelanotide met both coprimary endpoints over 24 weeks: improved sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo [3]. A 52-week extension sustained the desire improvement with no new safety signals [4]. The honest caveat sits right next to the win: critical re-analyses (Spielmans 2021, 2024) argue the effect is statistically significant but clinically small and have questioned the outcome measures. Earlier signals pointed the same direction — a single 20 mg intranasal dose increased self-reported moderate/high desire versus placebo (P=0.0114) in 18 premenopausal women with female sexual arousal disorder [7].
What is the PT-141 dosage for women?
In the RECONNECT trials and the US label, the studied and approved figure for premenopausal women with HSDD is 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than eight per month [6]. This is reported as a trial and label finding, not as a protocol for anyone to follow. The 1.75 mg dose was selected from a randomized dose-finding trial that compared 0.75, 1.25, and 1.75 mg, supported by a Phase 2b responder analysis [10][11]. The full PT-141 dosage and half-life picture, including pharmacokinetics, is set out separately.
How does PT-141 compare to flibanserin and testosterone for women?
Bremelanotide is an as-needed subcutaneous melanocortin agonist; flibanserin (the other approved HSDD medication) is a daily oral drug with a different mechanism; and testosterone is used off-label for some postmenopausal women rather than being approved for HSDD [3]. The three differ on route, on timing (as-needed injection versus daily pill), and on the populations studied. Recent comparative reviews of female sexual dysfunction contrast their differing effect and tolerability profiles; this site summarizes that the choice among them is a clinical one, decided with a qualified provider, not a ranking this digest makes.
Who the approval does not cover
The approval is narrow, and the boundary is worth stating. Bremelanotide is approved only for premenopausal women with acquired, generalized HSDD — not for postmenopausal women, not for men, and not for general sexual enhancement [3][6]. Use outside that group is off-label and is not supported by the trial evidence that earned the approval. For the male picture, which is investigational only, see how PT-141 works in the brain and its off-label section. The point is not to discourage anyone; it is to be exact about what the evidence actually licenses.